Vocal Markers from Sustained Phonation in Huntington’s Disease

Rachid Riad, Hadrien Titeux, Laurie Lemoine, Justine Montillot, Jennifer Hamet Bagnou, Xuan-Nga Cao, Emmanuel Dupoux, Anne-Catherine Bachoud-Lévi

Disease-modifying treatments are currently assessed in neurodegenerative diseases. Huntington’s Disease represents a unique opportunity to design automatic sub-clinical markers, even in premanifest gene carriers. We investigated phonatory impairments as potential clinical markers and propose them for both diagnosis and gene carriers follow-up. We used two sets of features: Phonatory features and Modulation Power Spectrum Features. We found that phonation is not sufficient for the identification of sub-clinical disorders of premanifest gene carriers. According to our regression results, Phonatory features are suitable for the predictions of clinical performance in Huntington’s Disease.

 DOI: 10.21437/Interspeech.2020-1057

Cite as: Riad, R., Titeux, H., Lemoine, L., Montillot, J., Bagnou, J.H., Cao, X., Dupoux, E., Bachoud-Lévi, A. (2020) Vocal Markers from Sustained Phonation in Huntington’s Disease. Proc. Interspeech 2020, 1893-1897, DOI: 10.21437/Interspeech.2020-1057.

  author={Rachid Riad and Hadrien Titeux and Laurie Lemoine and Justine Montillot and Jennifer Hamet Bagnou and Xuan-Nga Cao and Emmanuel Dupoux and Anne-Catherine Bachoud-Lévi},
  title={{Vocal Markers from Sustained Phonation in Huntington’s Disease}},
  booktitle={Proc. Interspeech 2020},